VALLADOLID, MARCH 25, 2026
53Biologics, a biotechnology company specialising in the development and manufacturing of biological drugs, has announced the closing of a strategic financing round led by the specialist European private equity firm Ren Life Sciences. Existing partners of the company co-invested, including leading Spanish innovation fund Inveready
The primary objective of this transaction is to consolidate 53Biologics’ position as a key player in Europe’s biomanufacturing infrastructure and will allow the company to drive various strategic initiatives, most notably:
- Expansion of GMP Capacity: Increasing production capacity to meet the growing global demand for monoclonal antibodies and other recombinant proteins.
- Consolidation of Capabilities: Offering end-to-end drug substance and drug product services across microbial and mammalian expression systems.
- International Expansion: Strengthening the company’s presence in international markets and positioning itself as a strategic partner for biopharmaceutical companies worldwide.
Pablo Gutiérrez, CEO of 53Biologics, highlighted the importance of this transaction for the company and for the Spanish and European biotech ecosystem: “This investment represents a clear endorsement of our vision: to offer flexible, high-quality solutions that accelerate the development and manufacturing of biological drugs for patients worldwide”. He also noted that the support from Ren Life Sciences and Inveready will enable the company to expand its industrial capabilities and respond with greater agility to the consistently rising global demand for biological therapies.
On behalf of Ren Life Sciences, Cristina Moratilla-Martin stated, “We are very pleased to lead this investment in 53Biologics. The company combines first-class technical expertise with a unique position in the development and manufacture of biological medicines. We have complete confidence in its team and its ability to establish itself as a key partner for the international biopharmaceutical industry”.
Roger Piqué, Partner at Inveready, commented: “At Inveready we are delighted to continue supporting 53Biologics, a company we have backed since our initial investment in 2018. Over these years, the company has demonstrated a strong ability to manage its growth efficiently, building first-class industrial facilities and a highly qualified management and technical team. We strongly believe in the company’s potential to further establish itself as a strategic partner for the international biopharmaceutical industry.”
Beyond industrial growth, the transaction will also have a significant impact on the scientific and technological ecosystem through the generation of new highly-skilled jobs in areas such as engineering, quality control and process development. This reinforces the strategic importance of having infrastructure and talent capable of meeting the current challenges of the biopharmaceutical industry.
About 53Biologics:
53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.
For more information or to speak with one of our experts email us at [email protected]
